| Literature DB >> 28363750 |
Hiroko Koyama1, Hiroshi Ikenuma2, Hiroshi Toda3, Goro Kondo3, Masaki Hirano3, Masaya Kato4, Junichiro Abe2, Takashi Yamada5, Toshihiko Wakabayashi3, Kengo Ito2, Atsushi Natsume6, Masaaki Suzuki7.
Abstract
O6-Benzylguanine (O6-BG) is a substrate of O6-methylguanine-DNA methyltransferase (MGMT), which is involved in drug resistance of chemotherapy in the majority of glioblastoma multiform. For clinical diagnosis, it is hoped that the MGMT expression level could be determined by a noninvasive method to understand the detailed biological properties of MGMT-specific tumors. We synthesized 11C-labeled O6-[(3-methyl)benzyl]guanine ([11C]mMeBG) as a positron emission tomography probe. Thus, a mixed amine-protected stannyl precursor, N9-(tert-butoxycarbonyl)-O6-[3-(tributylstannyl)benzyl]-N2-(trifluoroacetyl)guanine, was subjected to rapid C-[11C]methylation under [11C]CH3I/[Pd2(dba)3]/P(o-CH3C6H4)3/CuCl/K2CO3 in NMP, followed by quick deprotection with LiOH/H2O, giving [11C]mMeBG with total radioactivity of 1.34GBq and ≥99% radiochemical and chemical purities.Entities:
Keywords: (11)C labeling; Brain cancer imaging; O(6)-Benzylguanine; Positron emission tomography probe; Rapid C-[(11)C]methylation
Mesh:
Substances:
Year: 2017 PMID: 28363750 DOI: 10.1016/j.bmcl.2017.03.045
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823